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Three-Year Clinical and Audiological Outcomes of
Percutaneous Implants for Bone Conduction Devices: Comparison
Between Tissue Preservation Technique and Tissue
Reduction Technique
Ivo J. Kruyt, Herman Kok, Arjan Bosman, Rik Chre´tien Nelissen,
Emmanuel Antonia Maria Mylanus, and Myrthe Karianne Sofie Hol
Department of Otorhinolaryngology, Donders Center for Neurosciences, Radboud university medical centre,
Nijmegen, The Netherlands
Objectives: To evaluate the three-year clinical and audiolog-
ical outcomes of soft-tissue preservation compared to soft-
tissue reduction in linear incision surgery for percutaneous
implant for bone conduction (BC) devices.
Methods: Twenty-five patients (25 implants) were enrolled in
a prospective cohort for implant surgery with linear incision
and tissue preservation. The control group consisted of 25
patients (25 implants) from a previous randomized controlled
trial in which a linear incision with soft-tissue reduction was
applied. Follow-up visits were scheduled at 7 and 21 days
(fitting of sound processor); 12 weeks; 6 months; and at 1, 2,
and 3 years after implantation. Main outcome measures were
skin sensibility, soft-tissue status, Implant Stability Quotient
(ISQ), skin height, implant survival, revision surgery, scar
assessment, and hearing thresholds (BC in-situ between 250
Hz and 8 kHz with BC device on testband and abutment, and
BC thresholds at 250Hz–4 kHz with a B71 bone conductor).
Results: Tissue preservation resulted in superior sensibility
(mean percentage correct responses 99.7% [SD 1.7] vs
92.0% [SD 9.2], p¼ 0.0001). No spontaneous implant loss
occurred in either group. The abutment was removed in two
tests and in one control patient. Two control patients needed
skin revision surgery. Although not statistically significant,
more adverse soft-tissue reactions (Holgers 2) were
observed in the test-group (n¼ 9 [36%] vs n¼ 3 [12%],
p¼ 0.095). ISQ increased significantly more in the test group
compared to the control group (7.64 [SD 4.05] vs 4.29 [SD
3.93]). Skin thickening, scar assessment, and hearing out-
comes were comparable.
Conclusion: Tissue preservation demonstrated superior
skin sensibility compared to tissue reduction while other
clinical outcomes were comparably excellent. Abbrevia-
Abbreviations: AUC, area under the curve.—BC, bone
conduction.—BCD, bone conduction device.—ISQ, implant
stability quotient.—RFA, resonance frequency analysis.—
SD, standard deviation.
Key Words: BAHA—Bone conduction—Bone-anchored
hearing—Hearing loss—Holgers—Implant loss—implant sta-
bility—ISQ—Soft tissue reactions—Tissue preservation—
Tissue reduction—Wide-diameter implant.
Otol Neurotol 40:335–343, 2019.
Over the last decades, the surgical technique for
inserting percutaneous titanium implants in the temporal
bone, onto which bone conduction devices (BCDs) can
be coupled, has evolved, driven by the aim to reduce
postoperative complications, for example, adverse skin
reactions and implant loss. Until 2011, surgical implan-
tation was always combined with peri-implant soft-tissue
reduction, called skin thinning. The rationale behind skin
thinning was that by reducing the skin mobility around
the implant, the risk of inflammation and implant loss is
reduced, and skin overgrowing the abutment is avoided
(1–3). At the same time, however, skin thinning inflicts
more surgical trauma and compromises both blood flow,
thus hampering an optimal immune response during an
infection, and neural structures around the implant,
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causing numbness (4). In addition, skin thinning prolongs
the surgical procedure. In the past, different incision
techniques with skin thinning have been described, such
as the U-shaped flap, dermatome, and linear incision
technique (5–7). Although several studies indicate the
linear incision to be superior regarding clinical outcomes
(8,9), adverse skin reactions, osseointegration failure,
and the need for skin revision surgery still occur (10).
In 2011, after the introduction of wider diameter
implants and longer abutments, Hultcrantz (11) described
a modified linear incision technique without soft-tissue
reduction. By preserving the soft tissue, hence inflicting
less surgical trauma, it was hypothesized that this tech-
nique would result in less scar tissue formation and
numbness, cosmetic advantages, shorter surgery times,
faster wound healing, and possibly fewer skin infections.
A recent systematic review concluded that surgical tech-
niques with soft tissue preservation indeed have limited
postoperative skin complication rates and require less
surgical time compared to the skin-thinning techniques.
However, because different surgical techniques were
used in most comparative studies, no conclusions could
be drawn on which technique, that is, skin preservation or
skin reduction, is superior (12). The current study, a
continuation of the previously published 6-month fol-
low-up study, wherein short term and other data, such as
surgery duration, is reported (13), investigated the 3-year
clinical and audiological outcomes of the linear incision
surgical technique with soft-tissue preservation com-
pared to soft-tissue reduction.
MATERIALS AND METHODS
Ethical Considerations
The current study was performed in accordance with
the guidelines established in the Declaration of Helsinki (Wash-
ington 2002, ISO 14155), Good Clinical Practice (International
Conference on Harmonization Good Clinical Practice), and was
approved by the local ethical committee. The current study was
registered as NCT02064478 at www.Clinical-Trials.gov.
Study Design and Patients
The current study was designed as a prospective clinical trial
on soft-tissue preservation in implant surgery for BCDs (test
population) compared to a historical control population in which
soft-tissue reduction was performed. To be eligible for participa-
tion, patients indicated for a percutaneous BCD in our tertiary
referral centre had to be18 years and provide written informed
consent. Exclusion criteria were (i) bone thickness of <4mm at
the implant site; (ii) skin thickness of >10mm; (iii) inability to
participate in follow-upvisits; (iv.) history of psychiatric diseases
or mental disabilities; and (v) having a disease or treatment
known to compromise bone quality at the implant site (e.g.,
diabetes mellitus, radiation therapy, osteoporosis). These eligi-
bility criteria were identical for test and control group, except for
the exclusion criteria skin thickness of>10mm(in the test group)
and the need for >6mm abutment (in the control group).
The primary outcome of this study, skin sensibility around
the implant, was used as an outcome in a study on these implants
for the first time; therefore, no data were available for statistical
sample size calculations. Sample size was instead determined
pragmatically by the investigators’ experience, as well as on
practical feasibility. Twenty-five patients consented and were
consecutively included in the test group between February and
September 2014. The historical control group consisted of the
last 25 patients (having received 25 implants) of a previously
published randomized controlled clinical study implanted
betweenMarch 2013 and January 2014. These patients received
the same implant, placed using the same incision technique, but
with soft-tissue reduction instead of tissue preservation (14).
Two senior surgeons (EM and MH) performed all surgeries in
both groups.
Surgical Techniques, Implants, and Follow-Up
The same type of Wide Ponto implant (diameter 4.5mm,
length 4mm) with selected abutment was placed in a single-
staged surgical procedure using a standard linear incision tech-
nique, with either soft-tissue preservation (test), as originally
described byHultcrantz (11), or soft-tissue reduction (control), as
described by De Wolf et al (7). In both techniques, a linear
incision of approximately 30mm is made, followed by exposing
and mobilization of the periosteum. After the standard drilling
procedure, the implant is inserted in the mastoid bone. In the
reduction technique, subcutaneous tissue is then removed over an
area of approximately 2 cm around the incision. In contrast,
subcutaneous tissue is retained in the preservation technique.
In both techniques, the skin is then closed with sutures and
punctured at the implant location for the abutment to penetrate
the skin. In the test group, abutment length was determined based
on skin thicknessmeasured at the start of surgery before injection
of local anesthetics (0.5–3mm skin thickness¼ 6mm abutment;
3–6mm¼ 9mm; 6–10mm¼ 12mm). In the control group, all
patients underwent soft-tissue reduction with placement of a
6mmabutment (14). All implants and abutmentswere developed
by Oticon Medical AB (Askim, Sweden).
Follow-up visits in test groupwere scheduled at 7 and 21 days
(fitting of sound processor); 12 weeks; 6 months; and at 1, 2, and
3 years after implantation. Follow-up visits in the control group
were scheduled at identical time points, with additional visits at
14 and 28 days, and 6 weeks. Additional assessments, intended
for the current study, were included at the 12-month follow-up
visit and onward for control patients.
Outcome Measures
The primary objective of this study was to compare skin
sensibility around the abutment in the test group compared to
the control group. Sensibility was determined at six standard-
ized locations (Fig. 1A) using a broken wooden cotton swab to
determine gnostic (cotton side) and vital (sharp wooden side)
sensibility, and was reported as a percentage of correct answers.
In addition, subjective numbness was measured on a visual
analog scale (VAS)—from 0 (no numbness) to 10 (complete
numbness)—and by the patient reported diameter (centimeters)
of the numb area.
The secondary objectives were to investigate implant stabil-
ity over time (measured as Implant Stability Quotient, ISQ) and
to compare soft-tissue tolerability, skin height, implant survival,
the need for revision surgery, and scar assessment. ISQ was
objectively measured bymeans of resonance frequency analysis
(RFA), using a handheld Osstell ISQ device (Ostell AB,
Go¨teborg, Sweden) and a SmartPeg (type 55) attached to the
abutment. Perpendicular measurements result in two values,
recorded as an ISQ-low value and an ISQ-high value, respec-
tively. Soft-tissue tolerability was assessed according to
Holgers’ classification (15), in which a Holgers grade 2 or
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higher was considered an adverse skin reaction. Skin height was
evaluated in relation to the abutment (Fig. 1B). Scar assessment
was performed by means of the Patient and Observer Scar
Assessment Scale (POSAS) v2.0 (16). The POSAS consists of a
patient and an observer scale, containing six categories with
response options from 1 (normal skin) to 10 (worst imaginable).
The total score ranges from 6 to 60 for both scales. The patient
and the observer additionally score their overall opinion (not
included in the total scores).
To investigate a potential sound dampening effect of the
preserved soft tissue surrounding the abutment, BC in situ
thresholds were measured both with the patients’ sound pro-
cessor on abutment and on a testband. Furthermore, audiometric
BC thresholds (Interacoustics Equinox audiometer fitted with a
B71 transducer, Interacoustics, Assens, Denmark) were used to
check stability of the BC thresholds over time.
Data Analysis
Data management and statistical analyses were performed by
independent external data managers and biostatisticians (Sta-
tistiska Konsultgruppen, Go¨teborg, Sweden) and executed
according to a predefined statistical analysis plan.
For comparisons between groups, Fishers nonparametric
permutation test was used for numbness variables, Mantel–
Haenszel chi-square tests were used for all ordered categorical
variables, Fisher’s exact test was used for all dichotomous
variables, and Mann–Whitney U tests were used for all contin-
uous variables. Implant survival was analyzed with the log-rank
survival test between the two groups. Repeated measures
analyses were done for changes over time, using the Wilcoxon
signed rank tests for continuous variables and Sign test for
categorical and dichotomous variables. Due to differences in
abutment length in the test group, for ISQ values and functions
of ISQ values the adjusted analyses between the two groups was
performed with analysis of covariance (ANCOVA). Groups
were compared according to the intention-to-treat principle.
The number of visits varied between test and control groups.
Therefore, only data from follow-up visits available for both
groups were included in the analysis of visit-based data; for
cumulative variables all visits, including extra visits, were
included. All tests, performed by using SAS v9.4 (Cary,
NC), were two tailed and conducted at 0.05 significance level.
RESULTS
Patients and Follow-Up
The test population consisted of 25 patients with the
same number of implants. The historical control popula-
tion consisted of 25 patients with 25 implants. Demo-
graphics and baseline characteristics showed no
statistically significant differences between these study
groups (Table 1). No major perioperative complications
were observed in either group. In total, 45 patients (46
implants) completed the 3-year follow-up. Three patients
were withdrawn from the test group. The first patient had
his abutment electively removed after 30 months due to
persisting pain and minimal bleeding at the implant site
despite extensive antibiotic treatment and pain medica-
tion. The second patient wanted his abutment removed
after 26 months due to the burden of fast progressing
Lewy-body dementia. The third patient was lost to
follow-up, after missing multiple scheduled visits. His
last visit was performed 6 months after surgery, during
which he stated to only use the sound processor a few
hours per month. In the control group, one patient had his
abutment electively removed after 24 months in another
hospital due to disabling tinnitus, which was hoped to
improve by performing a stapedotomy combined with a
FIG. 1. (A) Sensibility test locations: at all locations both vital
(broken, sharp wooden side) and gnostic (cotton side of wooden
cotton swab) sensibility were tested in a random fashion. (B) Skin
height relative to abutment (A—under the shoulder of the
abutment; B—above the shoulder of the abutment; C—partial
overgrowth; D—complete overgrowth).
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normal air-conduction hearing aid (14). For all these
patients, data were included in the analysis up until
the moment of withdrawal.
Besides these withdrawn patients, only four follow-up
visits, in four different patients (two test patients and two
control patients), were missed or performed outside the
predefined visit window.
Skin Sensibility
The cotton swab sensibility test showed a significant
difference in median total sensibility (percentage of
correct answers): 99.7% (range 91.7–100%) in the test
group vs 92.0% (range 66.7–100%) in the control group
( p¼ 0.012) 36 months after surgery (see table, supple-
mental digital content 1, http://links.lww.com/MAO/
A725, which reports sensibility scores for each group
per visit). Moreover, 4% of the test patients experienced
numbness to some extent, compared to 52% of the
control patients. In line with this, subjective numbness
(VAS 0 [SD 0] vs VAS 0.9 [SD 1.6]) and patient reported
diameter of the numb area (0 cm [SD 0] vs 0.4 cm [SD
0.7]) also differed significantly in favor of the test group.
Skin sensibility at 12 and 36 months is displayed in
Figure 2.
Soft Tissue Tolerability and Complications
Figure 3 presents an overview of soft tissue reactions
per planned visit and all visits combined (including extra
visits). Across all visits, adverse skin reactions (Holgers
2–4) were observed in 36.0% of the test patients and in
12.0% of the control patients, which were all successfully
treated with locally applied ointment for 14 days. Neither
TABLE 1. Baseline characteristics
Variable Tissue Preservation group (n¼ 25) Tissue reduction group (n¼ 25) p-value
Gender
Male 15 (60.0%) 10 (40.0%)
Female 10 (40.0%) 15 (60.0%) 0.26
Age 51.5 (SD 13.4; range, 18.0; 73.0) 53.9 (SD 12.2; range, 30.0; 83.0) 0.55
Smoking 4 (16.0%) 4 (16.0%) 1.00
Indication
Acquired cond./mixed 21 (84.0%) 18 (72.0%) 0.50
Congenital conductive 1 (4.0%) 0 (0.0%) 1.00
Single-sided deafness 3 (12.0%) 7 (28.0%) 0.29
FIG. 2. Total skin sensibility test results at 12 and 36 months.
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adverse skin reactions ( p¼ 0.10) nor other postoperative
complications were significantly different between
groups: bleeding or hematoma (0% vs 0%; ( p¼ 1.0);
and skin dehiscence (0% vs 8% (all healed 3 weeks after
surgery); p¼ 0.49).
Thickening of the skin was observed in 56% (test) and
64% (control) of the patients, not statistically correlating
with the presence of an adverse skin reaction (Holgers
grade 2–4). Neither the maximum skin height observed
at all visits, nor skin height during any of the follow-up
visits differed between groups. Skin height per visit is
displayed in Figure 4. Only two control patients needed
revision surgery (6 weeks and 9 months after surgery,
respectively), both due to thickened skin (level B) around
the abutment without inflammation, resulting in feedback
issues (14).
POSAS
At 1-year follow-up, none of the categories on the
patient and observer scale exceeded scores of 4. The
patient categories thickness ( p¼ 0.031), irregularity
( p¼ 0.03), mean total patient score ( p¼ 0.01), and
overall opinion ( p¼ 0.003) differed significantly in
favor of the test group. The observer categories vascu-
larity ( p¼ 0.012), relief ( p¼ 0.004), surface area
( p< 0.0001), mean total observer score ( p¼ 0.0025),
and overall opinion ( p¼ 0.0004) differed significantly in
favor of the test group.
At 3-year follow-up, none of the categories on the
patient and observer scale exceeded scores of 3. The
patient category stiffness significantly ( p¼ 0.041) dif-
fered in favor of the control group. The observer catego-
ries relief ( p¼ 0.0037), and overall opinion ( p¼ 0.027),
differed significantly in favor of the test-group (see table,
supplemental digital content 1, http://links.lww.com/
MAO/A725, which reports the POSAS data per visit).
Implant and Abutment Survival
No implants were lost in either group. No statistically
significant difference in 3-year abutment survival was
observed between groups (test 92% vs control 96%): two
abutments were electively removed in the test group and
FIG. 3. Skin reactions (Holgers grade) at each visit and overall. The overall data also contain observations during unplanned extra visits.
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one in the control group (see section ‘patients and follow-
up’). The implant itself remained seated in all
three patients.
ISQ
As expected with differences in abutment length, the
mean 36-month AUC for ISQ-low was significantly
higher in the control group compared to the test-group
( p< 0.001). In both groups a significant increase in ISQ
low is observed over time ( p< 0.001), however, this
increase is significantly higher in the test group compared
to the control group (7.64 (SD4.1) vs 4.29 (SD3.9);
p¼ 0.0068) For ISQ high, similar results were observed,
with absolute numbers 1 to 2 points higher on average
and slightly less increase over time. ISQ data are dis-
played in Figure 5.
Audiology
After 36 months, no significant differences ( p>5%)
were seen for thresholds measured with testband and B-71
audiometric bone conductor when averaged across all
frequencies, indicating essentially similar hearing thresh-
olds. Also, BC-in-situ (i.e., on abutment) thresholds aver-
aged across 250Hz-8 kHz showed no difference between
test and control group (mean, 27.5 dB [SD12.3] vs 27.1 dB
[SD 14.0] p¼ 0.81). However, the 1000-Hz thresholds on
testband were statistically significantly different (mean
34.5 dB [SD 13.8] vs 25.0 dB [SD 14.4] p¼ 0.015). When
comparing individual thresholds on testband, abutment,
and B71 between test and control groupB71 and abutment
were not significantly different, but at 1000Hz, a signifi-
cant group effectwas observed for the differences between
abutment and testband thresholds (mean, -17.6 dB [SD
10.2] vs -9.0 dB [SD 6.1] p¼ 0.0016).
DISCUSSION
Synopsis of Key/New Findings
In current study, we compared the long-term clinical
outcomes of two different surgical techniques for
FIG. 4. Skin height relative to abutment by visit and overall per group. The overall data also contain observations during unplanned extra
visits.
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placing a percutaneous titanium implant for BCDs in the
temporal bone: the linear incision with soft tissue reduc-
tion and the linear incision with soft tissue preservation.
Based on our primary outcome measure, that is, skin
sensibility 3 years after surgery, patients operated
with tissue preservation experienced significantly less
numbness at the implant site compared to the tissue
reduction group. No differences were observed in the
total POSAS-scores, soft tissue tolerability, skin height
around the abutment, implant survival, and audiological
performance.
Strengths and Limitations of the Study
The current study is the first to compare long-term
clinical outcomes of two groups with tissue preservation
or reduction as the only variable. In addition, data quality
is considered very high, with only one patient lost-to-
follow-up and four visits outside the predefined
visit window.
At the study’s inception, skin sensibility was measured
for the first time in relationship to these surgical techni-
ques. A sample size could therefore not be calculated,
thus, was empirically chosen. In addition, by using a
historical control group randomization was not possible.
However, for both groups the same eligibility criteria
were applied, baseline characteristics were comparable,
and all data were gathered prospectively. Blinded follow-
up was not feasible, since the implant site appearance
differs between surgical techniques and longer abutments
were used in the test group.
Another limitation could be the difference in follow-up
visits. In the first 6 months of follow-up, patients in the
control group had three additional visits compared to the
test group. This might have influenced the quality of
the soft-tissue care, since more than half of adverse
soft-tissue reactions in the test group were observed at
the 6-month visit, and 77% of all reactions occurred in the
first 6 months after surgery. Nonetheless, no difference in
soft tissue reactions was observed at the 1-year interim
analysis and over the entire follow-up.
Comparisons with Other Studies
Postoperative numbness is evaluated in only two other
studies (17,18). In these studies, the linear incision
technique with tissue preservation is compared to the
dermatome technique with tissue reduction. In line with
our observations, both studies reported significantly less
numbness at the implant site for the tissue preservation
FIG. 5. Boxplot of ISQ low and ISQ high over time. ISQ indicates Implant Stability Quotient.
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group. However, caution is needed since a different skin
thinning technique was used (17,18).
A recent systematic review on soft tissue preservation
techniques concluded that postoperative skin complica-
tion rates were low and that overall complication rates
were comparable with skin-thinning techniques, while
the duration of the surgery was significantly shorter (12).
However, in only one comparative study, the same
incision technique, i.e. linear incision, was applied in
both skin-thinning group and tissue preservation group
(18). Despite the relatively high incidence of Holgers2
at 1 week (64% vs 67%), no significant differences in
cutaneous reactions after 1 year of follow-up were found
between groups (18), which is in line with the observa-
tions in the current study.
Clinical Applicability of the Study
The primary outcome, that is, skin sensibility, differed
significantly in favor of the tissue preservation tech-
nique. However, also patients operated with the reduc-
tion technique reported good sensibility scores and low
subjective numbness scores (VAS) in small correspond-
ing areas, which all improved over time. In addition, no
difference in subjective numbness was observed at
12 months despite significantly differing sensibility
scores. The significant differences on the POSAS after
12 months, in favor of the tissue preservation technique,
were overcome at the 3-year follow-up; especially the
total patient score in the control group improved (from
18.9 to 9.1). It is worth noting, however, that many
patients reported difficulties answering the POSAS
questions because of limited visibility and the lack of
interest in the appearance of the scar. Due to the position
of the implant, sensibility and appearance seem to be
of limited importance to patients, especially in the
long-term.
In the previous 6-month evaluation, significantly more
soft tissue reactions were observed in the tissue preser-
vation group (13). At the following visits, however, no
differences in soft tissue reactions were observed. As
such, over the entire follow-up, no significant difference
in adverse skin reactions were noticed between
surgical techniques.
Skin thickened in more than half of the patients,
regardless of the surgical technique. The skin height
per visit did not differ between groups. At the 36-month
follow-up skin thickening was observed in 18.2% (test)
and 33.3% (control) patients. This suggests that skin
thickening is often only temporary. The previous hypoth-
esis that thickening of the skin reflects the restoration of
normal soft tissue after soft tissue reduction seems
unlikely since skin thickening is also observed after
tissue preservation surgery (14). The hypothesis that skin
thickening could be the result of more active immuno-
logical mechanisms to compensate for the continuous
breach of the skin implied by the skin-penetrating
implant, seems more likely. However, we did not observe
any correlation with adverse skin reactions. Future
research, therefore, remains needed.
The difference in absolute ISQ scores (both low and
high) between groups was expected, since longer abut-
ments were used in the test group. Interestingly, the ISQ-
scores over time increased significantly more in the tissue
preservation group compared to the tissue reduction
group. Although this observation could suggest that
tissue preservation leads to a more rigid bone-implant
interface, we deem it unlikely that soft tissue handling
significantly influences osseointegration. Perhaps, the
stronger increase in ISQ could be assigned to measure-
ment error caused by the difference in abutment length,
which emphasizes the importance of not comparing ISQ
values of implants with different abutment lengths (19).
These results should be repeated by future studies with
similar protocols to affirm these assumptions.
The two statistically significant differences in fre-
quency specific BC thresholds between groups (BC-in-
situ threshold for 1000Hz on testband and the difference
between the BC-in-situ threshold on abutment and test-
band) were also, and to the same extent, observed in the
6-month evaluation (13). These differences can be most
likely attributed to differences in resonance frequency of
the sound processor in the transcutaneous conditions
(13,20). Nonetheless, since no differences were observed
between groups on the average thresholds measured on
testband, B71, and abutment, these indicate that the
preservation of soft tissue around the abutment has no
sound dampening effect.
CONCLUSION
A linear incision with soft-tissue preservation for the
implantation of percutaneous implants for BCDs is supe-
rior in terms of skin sensibility and scar appearance,
without influencing audiological outcomes, compared to
soft-tissue reduction. Both surgical techniques have com-
parable implant survival and soft tissue tolerability. Also
taking into account the shorter surgery time, we advocate
using the soft-tissue preservation technique.
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